In vivo Efficacy and Safety Evaluation of Lactosyl-β-cyclodextrin as a Therapeutic Agent for Hepatomegaly in Niemann-Pick Type C Disease
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
In vivo Efficacy and Safety Evaluation of Lactosyl-β-cyclodextrin as a Therapeutic Agent for Hepatomegaly in Niemann-Pick Type C Disease
Authors
Keywords
-
Journal
Nanomaterials
Volume 9, Issue 5, Pages 802
Publisher
MDPI AG
Online
2019-05-27
DOI
10.3390/nano9050802
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of 6- O -α-maltosyl-β-cyclodextrin in lysosomal cholesterol deprivation in Npc1- deficient Chinese hamster ovary cells
- (2018) Yasuyo Okada et al. CARBOHYDRATE RESEARCH
- Cholesterol lowering effects of mono-lactose-appended β-cyclodextrin in Niemann–Pick type C disease-like HepG2 cells
- (2015) Keiichi Motoyama et al. Beilstein Journal of Organic Chemistry
- Efficacy of 2-Hydroxypropyl-β-cyclodextrin in Niemann–Pick Disease Type C Model Mice and Its Pharmacokinetic Analysis in a Patient with the Disease
- (2015) Yuta Tanaka et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease
- (2015) Charles H. Vite et al. Science Translational Medicine
- Small regulators, major consequences - Ca2+ and cholesterol at the endosome-ER interface
- (2014) R. van der Kant et al. JOURNAL OF CELL SCIENCE
- In Vitro and In Vivo Study of Gal-OS Self-Assembled Nanoparticles for Liver-Targeting Delivery of Doxorubicin
- (2014) Hejian Guo et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- How calcium makes endocytic receptors attractive
- (2014) Christian B.F. Andersen et al. TRENDS IN BIOCHEMICAL SCIENCES
- Miglustat: A Review of Its Use in Niemann-Pick Disease Type C
- (2013) Katherine A. Lyseng-Williamson DRUGS
- Lung toxicity of hydroxypropyl-β-cyclodextrin infusion
- (2013) Yin-Hsiu Chien et al. MOLECULAR GENETICS AND METABOLISM
- Treatment of Niemann–Pick Type C Disease by Histone Deacetylase Inhibitors
- (2013) Paul Helquist et al. Neurotherapeutics
- Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: Lost and found
- (2012) Eirini I. Rigopoulou et al. AUTOIMMUNITY REVIEWS
- Lysosomal storage disorders: The cellular impact of lysosomal dysfunction
- (2012) Frances M. Platt et al. JOURNAL OF CELL BIOLOGY
- Quantitative role of LAL, NPC2, and NPC1 in lysosomal cholesterol processing defined by genetic and pharmacological manipulations
- (2011) Charina M. Ramirez et al. JOURNAL OF LIPID RESEARCH
- Niemann-Pick disease type C
- (2010) Marie T Vanier Orphanet Journal of Rare Diseases
- Weekly Cyclodextrin Administration Normalizes Cholesterol Metabolism in Nearly Every Organ of the Niemann-Pick Type C1 Mouse and Markedly Prolongs Life
- (2010) Charina M Ramirez et al. PEDIATRIC RESEARCH
- Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid
- (2009) Benny Liu et al. JOURNAL OF LIPID RESEARCH
- Chronic Cyclodextrin Treatment of Murine Niemann-Pick C Disease Ameliorates Neuronal Cholesterol and Glycosphingolipid Storage and Disease Progression
- (2009) Cristin D. Davidson et al. PLoS One
- Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells
- (2009) L. Abi-Mosleh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse
- (2009) B. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium
- (2008) Emyr Lloyd-Evans et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started